Clinical trial NCT01752049: Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Official title: Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hereditary Hemorrhagic Telangiectasia
Keywords: Hereditary Hemorrhagic Telangiectasia
Anti-angiogenic Therapy
vascular malformations
HHT
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
Collaborators: name: University of California, San Francisco
name: The Hospital for Sick Children
name: University of Toronto
name: Sunnybrook Health Sciences Centre
name: Toronto Metropolitan University
name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2012-12-18
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized by the development of abnormal connections between arteries and veins throughout the body, called vascular malformations. These abnormal blood vessels are referred to as arteriovenous malformations (AVM) if they are large and telangiectasias if they are small. Telangiectasias develop due to irregular growth of blood vessels.

Anti-angiogenic therapy, such as the drug Apo-Timop, curbs the growth of new blood vessels. Apo-Timop is included in a class of medications called beta-blockers. Anti-angiogenic therapies exert their beneficial effects in a number of ways: by disabling the agents that activate and promote cell growth, or by directly blocking the growing blood vessel cells.

The investigators think that anti-angiogenic therapy may lead to the shrinking of telangiectasia in people with HHT. The investigators hope that this study will provide us with proof of this concept and might lead to the development and study of anti-angiogenic therapies to help improve the lives of individuals with vascular malformations.

Detailed description: This is a small study of 5 patients from St. Michael's Hospital who have HHT and at least 5 typical telangiectasias.

Patients who anticipate a major surgery during this study or are pregnant, breast feeding or on other beta blocker medication may not enroll in this study.

This study lasts 12 weeks (84 days). During this time, subjects will apply a drop of either Apo-timop 0.5% or a placebo solution to 4 telangiectasias twice daily.

The active study medication is called Apo-Timop and is a clear liquid solution stored in a bottle. An eye dropper is used for application.

* Apo-timop will be applied to 3 telangiectasias and
* a placebo will be applied to one telangiectasia A placebo is an inactive substance, with no active medication in it, and it looks the same as the real medication. There is no potential harm of receiving the placebo. It is necessary to use a placebo to make sure that the effect of Apo-timop can be determined without any bias.

Subjects will receive four numbered bottles for every 28 day period as well as a photo which indicates which bottle is to be applied to which telangiectasia.

Neither the subject nor the research staff will know which telangiectasia will receive the placebo.

Apo-timop, is not part of the standard therapeutic regimen for HHT. It is a Health Canada approved medication which is applied as an eye drop, that has been shown to reduce pressure in the eye and is commonly used for glaucoma.

Eligibility criteria: Inclusion Criteria:

1. Definite clinical or genetic diagnosis of HHT
2. Known ENG or ALK1 mutation (personal or familial)
3. Age\>=18 years
4. At least 5 typical (round/ovoid, not spider or linear) cutaneous telangiectasia (size range 2-5mm) on hands (not including lesions on over inter-phalangeal joints) or face

Exclusion Criteria:

1. Contraindication to systemic beta-blocker (severe asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt heart failure, hypotension, allergy/intolerance/ hypersensitivity to timolol)
2. Current treatment with systemic beta-blocker
3. Current participation in other therapeutic trial for HHT
4. Current pregnancy or breastfeeding.

Primary outcomes:
measure: Change in Lesion Area of Treated Telangiectasia.
timeFrame: 84 days
Secondary outcomes:
measure: Descriptive Changes in Histopathology in Baseline vs Treated Lesions
timeFrame: 84 days
measure: Serum Angiogenic Markers
timeFrame: 84 days
measure: Stability of Area of Untreated Telangiectasias Over the 84 Day Period
timeFrame: 84 days
measure: Blood Flow Velocity and Volume Flow Rates
timeFrame: 84 days
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Marie E Faughnan, MD MSc FRCPC
role: PRINCIPAL_INVESTIGATOR
References: